Tadalafil
- Generic Name
- Tadalafil
- Brand Names
- Adcirca, Alyq, Cialis, Entadfi, Tadliq, Talmanco (previously Tadalafil Generics), Tadalafil Mylan, Tadalafil Lilly, Adcirca (previously Tadalafil Lilly)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19N3O4
- CAS Number
- 171596-29-5
- Unique Ingredient Identifier
- 742SXX0ICT
- Background
Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy. It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibitors like sildenafil, tadalafil has greater selectivity for PDE5 and a longer half-life which has made it a more suitable option for chronic once-daily dosing in the treatment of PAH.
- Indication
Tadalafil is indicated for the treatment of erectile dysfunction (ED) and either alone or in combination with finasteride for the treatment of benign prostatic hypertrophy (BPH). It is also indicated for the treatment of pulmonary arterial hypertension (PAH) both alone and in combination with macitentan or other endothelin-1 antagonists.
- Associated Conditions
- Benign Prostatic Hyperplasia (BPH), Erectile Dysfunction, Pulmonary Arterial Hypertension (PAH)
- Associated Therapies
- -
A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms
- Conditions
- Interventions
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2013-02-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 696
- Registration Number
- NCT01139762
- Locations
- ๐น๐ท
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Izmir, Turkey
A Study in Erectile Dysfunction
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 623
- Registration Number
- NCT01130532
- Locations
- ๐จ๐ฆ
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Saskatoon, Saskatchewan, Canada
A Study in Patients With Erectile Dysfunction
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 770
- Registration Number
- NCT01122264
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Plymouth, Devon, United Kingdom
A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
- Conditions
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2010-05-10
- Target Recruit Count
- 66
- Registration Number
- NCT01117298
- Locations
- ๐ฎ๐ณ
Department of Immunology, SGPGIMS, Lucknow, UP, India
๐ฎ๐ณImmunology Rheumatology Unit, IPGMER, Kolkatta, WB, India
๐ฎ๐ณMedicine Unit II, PGIMER, Chandigarh, Punjab, India
Tadalafil in Becker Muscular Dystrophy
- First Posted Date
- 2010-02-18
- Last Posted Date
- 2013-08-20
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 48
- Registration Number
- NCT01070511
- Locations
- ๐บ๐ธ
Cedars-Sinai Medical Center, Los Angeles, California, United States
๐บ๐ธCedars Sinai Medical Center, Los Angeles, California, United States
Effect of Tadalafil (Cialis) on the Cardiovascular System of Spinal Cord Injury (SCI) Males
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2015-07-17
- Lead Sponsor
- University of Manitoba
- Target Recruit Count
- 20
- Registration Number
- NCT01067391
- Locations
- ๐จ๐ฆ
Health Sciences Centre Rehabilitation Hospital, Winnipeg, Manitoba, Canada
Post Marketing Observational Study in Patients With Pulmonary Arterial Hypertension
- First Posted Date
- 2010-02-10
- Last Posted Date
- 2015-10-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 1809
- Registration Number
- NCT01066845
A Study of Tadalafil After Radical Prostatectomy
- First Posted Date
- 2009-12-04
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 583
- Registration Number
- NCT01026818
- Locations
- ๐ฌ๐ง
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Withington, Manchester, United Kingdom
Tadalafil in Preventing Erectile Dysfunction in Patients With Prostate Cancer Treated With Radiation Therapy
- Conditions
- Interventions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2018-02-14
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 242
- Registration Number
- NCT00931528
- Locations
- ๐บ๐ธ
Providence Hospital, Mobile, Alabama, United States
๐บ๐ธArizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
๐บ๐ธMayo Clinic in Arizona, Scottsdale, Arizona, United States
A Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract
- Conditions
- Interventions
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2019-06-11
- Target Recruit Count
- 45
- Registration Number
- NCT00894413
- Locations
- ๐บ๐ธ
Johns Hopkins Hospital, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.